A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Novartis Ag stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 17,360 shares of NVS stock, worth $1.9 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
17,360
Previous 10,922 58.95%
Holding current value
$1.9 Million
Previous $1.06 Million 75.0%
% of portfolio
0.08%
Previous 0.15%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

BUY
$92.57 - $107.37 $595,965 - $691,248
6,438 Added 58.95%
17,360 $1.85 Million
Q1 2024

Apr 11, 2024

BUY
$95.27 - $108.47 $470,919 - $536,167
4,943 Added 82.67%
10,922 $1.06 Million
Q4 2023

Jan 08, 2024

BUY
$92.27 - $101.54 $551,682 - $607,107
5,979 New
5,979 $603,000

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $235B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Wiley Bros. Aintree Capital, LLC Portfolio

Follow Wiley Bros. Aintree Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wiley Bros. Aintree Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wiley Bros. Aintree Capital, LLC with notifications on news.